Search the PBPK Model Repository

Quickly find freely available drug and population models in our PBPK model repository.

The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Found 149 Matches

Amodiaquine

Brand Name(s) include: Basoquin, Camoquin, Flavoquin, Coarsucam

Disease: Malaria

Drug Class: Antimalarials

Date Updated: June 2021

The model at-a-glance

  Absorption Model

First-Order

  Volume of Distribution

Full PBPK (Method 2)

  Route of Elimination

CYP2C8 = 72%; Additional HLM = 28%

  Perpetrator DDI

  • CYP2D6 

  Validation

  • Four clinical studies describing single and multiple dose exposure of amodiaquine were used to verify the PBPK model. In comparison of predicted vs. observed AUC, 75% of the studies were 2-fold and 50% were within 1.5-fold. A clinical DDI study where amodiaquine was the victim of a CYP2C8-mediated DDI was accurately recovered using the PBPK model.

  Limitations

  • Clinical data has not been used to verify amodiaquine as a perpetrator of CYP2D6-mediated DDIs

  Updates in V19

  • Updated in vitro­ data
    • fu: 0.033 -> 0.089
    • B:P: 1.3 -> 1.1
    • DEAQ Ki for CYP2D6 (µM) – 1.7 -> 1.6
  • Converted from minimal PBPK model to full PBPK model
    • Recalculated retrograde clearance for CYP2C8 CLint and additional HLM CLint

 

Desloratadine_V14R1_AstraZeneca_20200427
Desloratadine adult compound file for paediatric prediction.
Meropenem_V14R1_AstraZeneca_20200327
Meropenem for pediatric prediction.
Montelukast_V14R1_AstraZeneca_20200427
Montelukast adult compound file for paediatric prediction.

|<

<

20

21

22

23

24

25

26

27

28

29

30

31

32

33

>

>|